AB RESP-E

AB RESP-E

COMPOSITION

ACEBROPHYLLINE..............100mg

ERDOSTEINE...........300mg

AB-RESP E      - Monograph

Acebrophylline 100 mg + Erdosteine 300 mg Acebrophylline— mucoregulator · bronchodilator Erdosteine— mucolytic · antioxidant

One tablet, two complementary actions

Chronic bronchitis and COPD exacerbations are driven by thick, adherent mucus, narrowed airways, and ongoing oxidative airway inflammation. This combination pairs a xanthine-derivative mucoregulator with a thiol mucolytic so that airway clearance and airflow are addressed together, rather than one at a time.

Acebrophylline

Theophylline-7-acetate + ambroxol moiety

·        Relaxes bronchial smooth muscle by inhibiting phosphodiesterase III/IV, raising intracellular cAMP

·        Stimulates pulmonary surfactant production, easing mucus expulsion

·        Suppresses phospholipase A₂, reducing leukotriene and TNF-driven inflammation

Erdosteine

Thiolactone pro-drug

·        Active thiol metabolites cleave mucus disulfide bonds, lowering viscosity

·        Scavenges free radicals from smoke and inflammatory stress, protecting airway epithelium

·        Improves antibiotic penetration into sputum during infective exacerbations

·        Reduce bacterial adhesion to the epithelial cells.

Net effect: easier expectoration, reduced bronchial hyper-responsiveness, and antioxidant cover during acute exacerbations of chronic bronchitis and COPD.

Composition

Each film-coated Bilayered tablet contains:

 

Active ingredient

Strength

Role

Acebrophylline

100 mg

Mucoregulator & bronchodilator

Erdosteine

300 mg

Mucolytic & antioxidant

Indications Use in

·        Acute exacerbations of chronic bronchitis with thick, difficult-to-clear sputum

·        Chronic obstructive pulmonary disease (COPD) with persistent productive cough

·        Bronchial asthma with mucus hypersecretion, as an adjunct to bronchodilator therapy

·        Adjunct to antibiotic therapy during infective exacerbations, to aid sputum penetration


Not recommended in

·        Known hypersensitivity to ambroxol, theophylline/xanthine derivatives, or erdosteine

·        Active peptic ulcer disease

·        Severe renal impairment (creatinine clearance < 25 mL/min) or hepatic cirrhosis

·        Recent myocardial infarction, hemodynamic instability, or significant arrhythmia

·        Pregnancy and lactation, unless benefit clearly outweighs risk

Dosage & administration

To be taken strictly as prescribed. Final posology and duration are at the physician's discretion.

1.     Adults - One tablet twice daily, after food, with a full glass of water.

2.     Duration - Typically continued through the acute exacerbation; courses beyond 10 days should be physician-reviewed, per erdosteine's labelled posology.

3.     Hepatic impairment - Use with caution; avoid exceeding recommended daily exposure in mild hepatic impairment, and avoid entirely in cirrhosis.

4.     Elderly & renal impairment - Dose adjustment may be required; avoid if creatinine clearance is below 25 mL/min.

Safety information Common adverse effects

Gastrointestinal discomfort, nausea, heartburn, loss of appetite, headache, and mild drowsiness. Most are dose-related and self-limiting.

Watch for

Rash, itching, or breathing difficulty warrant discontinuation. Fever or chills during therapy should prompt immediate medical review.

Drug interactions

Caution with concurrent xanthine derivatives, potassium-losing diuretics (e.g. furosemide), and hormonal contraceptives, which may alter clearance.

 

 

 

Special populations

Not established for use in children. Caution advised in patients under 18 and in those with a history of stomach ulcers.

For the use of a Registered Medical Practitioner, Hospital, or Laboratory only. This brochure summarizes published pharmacological and prescribing information on acebrophylline and erdosteine and is intended as a formulation overview

— it does not replace the approved package insert. Prescribers should confirm current indications, contraindications, and dosing against the product's official prescribing information before use.

 

AB-RESP E is marketed by Exmo Biogenics Pvt Ltd